Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices [Paperback]

High-level commentary on various facets of the pharmaceutical industry from a key leader in the field

This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension.

Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered and questions explored within the work include:

• Fiscal consequences of curing hepatitis C
• mRNA vaccines and the race for a cure
• Why the government does not deserve a piece of Biopharmas profits
• Paying for drugs whose ultimate value is unknown
• The impact of reduced revenues on R&D

This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.

Acknowledgments ix

Introduction x

Chapter 1 The $1000 Pill: the Fiscal Consequences of Curing Hepatitis C 1

Chapter 2 Enter the Payers: Fda Approval Does Not Guarantee Commercial Success 10

Chapter 3 Pandemic: mRNA Vaccines And The Race For A Cure 19

Chapter 4 Federal Investment in R&d: Why the Government Does Not Deserve a Piece of Biopharmas Profits? 34

Chapter 5 Insulin: the True Cost of a 100- Year- Old Drug 44